目的 评估结直肠癌(CRC)患者抗肿瘤治疗期间使用电子化患者报告结局( ePRO)工具进行症状管理的依从性及 其影响因素。 方法 回顾性分析 2023 年 1 月至 11 月从全国 36 家医院招募的符合纳入排除标准的 326 例 CRC 患者数据,使用 总体应答率(ORR)、平均应答率(ARR)、单次应答率(SRR)、患者水平的应答率(PRR)评估 CRC 患者抗肿瘤治疗期间对使用 ePRO 工具的依从性,并使用广义线性混合效应模型分析 CRC 患者使用 ePRO 工具依从性的影响因素。 结果 抗肿瘤治疗期间 CRC 患者对 ePRO 工具中不同模块的 ORR 范围为 31. 98% ~ 60. 36%,ARR 范围为 31. 49% ~ 62. 09%,不同治疗周期总数的 CRC 患者对 ePRO 工具的 PRR 均值介于 27. 33%和 51. 15%之间。 年龄<40 岁、CRC 分期为Ⅱ期和Ⅲ期、居住在乡村地区、接 受免疫治疗的 CRC 患者对 ePRO 工具的依从性相对较高。 结论 临床诊疗环境中 CRC 患者抗肿瘤治疗期间对使用 ePRO 工具 的依从性相对较低,应通过加强宣教、优化 ePRO 工具及强化医患反馈机制等途径,进一步提高 CRC 患者对 ePRO 工具的依从 性,从而充分发挥 ePRO 工具在 CRC 患者症状管理中的临床价值。

Objective To evaluate the adherence and influencing factors of colorectal cancer CRC patients using electronic patient-reported outcome ePRO tool for symptom management during anti -tumor therapy. Method A retrospective analysis was conducted on data of 326 CRC patients recruited from 36 hospitals nationwide from January to November 2023. Adherence to ePRO tool during anti-tumor therapy was assessed using overall response rate ORR average response rate ARR single response rate SRR and patient-level response rate PRR . The generalized linear mixed model was used to analyze factors influencing the use of ePRO tool. Result During anti-tumor therapy ORR of CRC patients ranging from 31. 98% to 60. 36% and ARR from 31. 49% to 62. 09% across different ePRO tool modules. The mean PRR of CRC patients varied between 27. 33% and 51. 15% depending on the total number of treatment cycles. Higher adherence was observed in younger patients those with stage Ⅱ and Ⅲ CRC patients residing in rural areas and those receiving immunotherapy. Conclusion Adherence to ePRO tools during anti-tumor therapy in CRC patients in clinical settings is relatively low. To enhance the adherence of CRC patients to ePRO tools and thereby maximize their clinical utility in symptom management efforts should be directed towards strengthening patient education optimizing the design of ePRO tools and reinforcing the feedback mechanisms between healthcare providers and patients.